Newsroom | 8527 results

Sorted by: Latest
Publishing
-

Meiji Seika Pharma : résultats positifs de l’essai de phase III Integral-1 sur le nacubactam, un nouvel inhibiteur de β-lactamase, dans le traitement des infections compliquées des voies urinaires ou de la pyélonéphrite aiguë non compliquée...

TOKYO--(BUSINESS WIRE)--  Meiji Seika Pharma : résultats positifs de l’essai de phase III Integral-1 sur le nacubactam, un nouvel inhibiteur de β-lactamase, dans le traitement des infections compliquées des voies urinaires ou de la pyélonéphrite aiguë non compliquée ― Publiés dans The Lancet Meiji Seika Pharma Co., Ltd. (siège social à Tokyo ; président-directeur général : Toshiaki Nagasato) a annoncé aujourd’hui que les résultats de l’étude Integral-1, l’un des deux essais cliniques mondiaux d...
-

Riassunto: Meiji Seika Pharma: risultati positivi da Integral-1, lo studio clinico di fase III su nacubactam, un nuovo inibitore delle β-lattamasi, nel trattamento delle infezioni del tratto urinario complicate o nella pielonefrite acuta non complicata...

TOKYO--(BUSINESS WIRE)--  Meiji Seika Pharma: risultati positivi da Integral-1, lo studio clinico di fase III su nacubactam, un nuovo inibitore delle β-lattamasi, nel trattamento delle infezioni del tratto urinario complicate o nella pielonefrite acuta non complicata, pubblicati in The Lancet Meiji Seika Pharma Co., Ltd. (con sede a Tokyo; Presidente e Direttore rappresentante: Toshiaki Nagasato) oggi ha annunciato che i risultati dello studio Integral-1, uno di due studi clinici globali di fas...
-

Meiji Seika Pharma: Positive Ergebnisse der Phase-III-Studie Integral-1 zu Nacubactam, einem neuartigen β-Lactamase-Hemmer, bei komplizierten Harnwegsinfektionen oder akuter unkomplizierter Pyelonephritis werden in The Lancet veröffentlicht

TOKIO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (Hauptsitz in Tokio; President und Representative Director: Toshiaki Nagasato) gab heute bekannt, dass die Ergebnisse der Integral-1-Studie, einer von zwei globalen klinischen Phase-III-Studien zur Bewertung der Wirksamkeit und Sicherheit des neuartigen β-Lactamase-Hemmers Nacubactam (Tntwicklungscode: OP0595), in The Lancet veröffentlicht wurden. Der Artikel lautet „Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared...
-

Resumen: Meiji Seika Pharma: The Lancet publica resultados positivos del ensayo Integral-1 de fase 3 de nacubactam, un nuevo inhibidor de β-lactamasa, en infecciones urinarias complicadas o pielonefritis agudas no complicadas

TOKIO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (oficinas centrales: Tokio; presidente y director representante: Toshiaki Nagasato) anunció hoy que los resultados del estudio Integral-1, uno de dos ensayos clínicos de fase 3 globales que evalúan la eficacia y la seguridad de nacubactam (código de desarrollo: OP0595), su nuevo inhibidor de β-lactamasa, fueron publicados en The Lancet. El artículo se titula “Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with im...
-

Samenvatting: Meiji Seika Pharma komt met positieve resultaten van de fase III-studie Integral-1 met nacubactam, een nieuwe β-lactamase-remmer, bij gecompliceerde urineweginfecties of acute ongecompliceerde pyelonefritis ― Gepubliceerd in The Lancet

TOKIO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (hoofdkantoor in Tokio; president en vertegenwoordigend directeur: Toshiaki Nagasato) heeft vandaag bekendgemaakt dat de resultaten van de Integral-1-studie, een van de twee wereldwijde fase III-klinische onderzoeken naar de werkzaamheid en veiligheid van zijn nieuwe β-lactamase-remmer nacubactam (ontwikkelingscode: OP0595), zijn gepubliceerd in The Lancet. Het artikel heeft als titel "Efficacy and safety of cefepime–nacubactam and aztreonam–...
-

Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma reports positive Phase III Integral-1 results for nacubactam, a novel β-lactamase inhibitor, in cUTI/AP — published in The Lancet....
-

The William Morrow Group Presents Exceptional Titles for Father’s Day 2026 Book-Gifting Roundups

NEW YORK--(BUSINESS WIRE)--The William Morrow Group announces a curated selection of titles perfect for media inclusion in Father’s Day 2026 book-gifting roundups....
-

Dark Reading Celebrates 20 Years as a Leading Authority on Cybersecurity, Highlighting the People, Events, Ideas, and Technologies Shaping the Modern Risk Landscape

NEWTON, Mass.--(BUSINESS WIRE)--Informa TechTarget is celebrating the 20th anniversary of Dark Reading, its leading online cybersecurity publication....
-

Moving Film “Dee & Dan” Documents a Day Living With Niemann-Pick Disease as an Intimate Portrait of Resilience

CHICAGO & NEW YORK & SAN DIEGO--(BUSINESS WIRE)--A powerful new short film debuts today as the first production in the In the Light film series from 24/364....
-

Two New TV Shows Confront the Defining Forces of Our Time—AI, Energy, and the Future of Civilization

HOUSTON--(BUSINESS WIRE)--NOWMEDIA Television Networks today announced the debut of two original series hosted by tech entrepreneur and bestselling author Todd Thomas: Abundant Energy and Infinite Future—two ambitious shows designed to tackle the most urgent and consequential shifts shaping the global economy. At a time when artificial intelligence is accelerating human capability while simultaneously straining the world’s energy systems, these series bring clarity, urgency, and solutions to th...